CN113999241B - 一种合成三尖杉碱中间体的方法 - Google Patents
一种合成三尖杉碱中间体的方法 Download PDFInfo
- Publication number
- CN113999241B CN113999241B CN202111499183.2A CN202111499183A CN113999241B CN 113999241 B CN113999241 B CN 113999241B CN 202111499183 A CN202111499183 A CN 202111499183A CN 113999241 B CN113999241 B CN 113999241B
- Authority
- CN
- China
- Prior art keywords
- compound
- cephalotaxine
- synthesizing
- allyl
- amide compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- DSRNKUZOWRFQFO-UHFFFAOYSA-N cephalotaxine Natural products COC1=CC23CCCN2CCc4cc5OCOc5cc4C3=C1O DSRNKUZOWRFQFO-UHFFFAOYSA-N 0.000 title claims abstract description 41
- YMNCVRSYJBNGLD-KURKYZTESA-N cephalotaxine Chemical compound C([C@@]12C=C([C@H]([C@H]2C2=C3)O)OC)CCN1CCC2=CC1=C3OCO1 YMNCVRSYJBNGLD-KURKYZTESA-N 0.000 title claims abstract description 40
- 238000000034 method Methods 0.000 title claims abstract description 26
- 230000002194 synthesizing effect Effects 0.000 title claims abstract description 18
- -1 Boc amide compound Chemical class 0.000 claims abstract description 66
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims abstract description 35
- 238000006243 chemical reaction Methods 0.000 claims abstract description 25
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract description 18
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 41
- 239000000543 intermediate Substances 0.000 claims description 34
- 230000015572 biosynthetic process Effects 0.000 claims description 28
- 238000003786 synthesis reaction Methods 0.000 claims description 28
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 24
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 21
- 239000003960 organic solvent Substances 0.000 claims description 19
- 239000002904 solvent Substances 0.000 claims description 18
- 238000004440 column chromatography Methods 0.000 claims description 17
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 15
- 238000001704 evaporation Methods 0.000 claims description 15
- 150000008627 azaspiro compounds Chemical class 0.000 claims description 14
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 12
- 239000003513 alkali Substances 0.000 claims description 12
- XXROGKLTLUQVRX-UHFFFAOYSA-N hydroxymethylethylene Natural products OCC=C XXROGKLTLUQVRX-UHFFFAOYSA-N 0.000 claims description 11
- 238000010992 reflux Methods 0.000 claims description 11
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 10
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 10
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 8
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 claims description 8
- 239000003153 chemical reaction reagent Substances 0.000 claims description 8
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 8
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 claims description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 7
- 238000001035 drying Methods 0.000 claims description 7
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical group CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 6
- 125000003118 aryl group Chemical group 0.000 claims description 6
- ABBZJHFBQXYTLU-UHFFFAOYSA-N but-3-enamide Chemical class NC(=O)CC=C ABBZJHFBQXYTLU-UHFFFAOYSA-N 0.000 claims description 6
- 239000003638 chemical reducing agent Substances 0.000 claims description 6
- 238000001816 cooling Methods 0.000 claims description 6
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 6
- FCDPQMAOJARMTG-UHFFFAOYSA-M benzylidene-[1,3-bis(2,4,6-trimethylphenyl)imidazolidin-2-ylidene]-dichlororuthenium;tricyclohexylphosphanium Chemical compound C1CCCCC1[PH+](C1CCCCC1)C1CCCCC1.CC1=CC(C)=CC(C)=C1N(CCN1C=2C(=CC(C)=CC=2C)C)C1=[Ru](Cl)(Cl)=CC1=CC=CC=C1 FCDPQMAOJARMTG-UHFFFAOYSA-M 0.000 claims description 5
- 239000003054 catalyst Substances 0.000 claims description 5
- 238000003756 stirring Methods 0.000 claims description 5
- 238000005406 washing Methods 0.000 claims description 5
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical group CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 4
- 239000012445 acidic reagent Substances 0.000 claims description 4
- 230000002152 alkylating effect Effects 0.000 claims description 4
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 4
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 claims description 4
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 4
- 239000007818 Grignard reagent Substances 0.000 claims description 3
- SMZOGRDCAXLAAR-UHFFFAOYSA-N aluminium isopropoxide Chemical group [Al+3].CC(C)[O-].CC(C)[O-].CC(C)[O-] SMZOGRDCAXLAAR-UHFFFAOYSA-N 0.000 claims description 3
- YWEUIGNSBFLMFL-UHFFFAOYSA-N diphosphonate Chemical compound O=P(=O)OP(=O)=O YWEUIGNSBFLMFL-UHFFFAOYSA-N 0.000 claims description 3
- CYSFUFRXDOAOMP-UHFFFAOYSA-M magnesium;prop-1-ene;chloride Chemical group [Mg+2].[Cl-].[CH2-]C=C CYSFUFRXDOAOMP-UHFFFAOYSA-M 0.000 claims description 3
- DLYUQMMRRRQYAE-UHFFFAOYSA-N phosphorus pentoxide Inorganic materials O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 claims description 3
- 230000003113 alkalizing effect Effects 0.000 claims description 2
- 239000002168 alkylating agent Substances 0.000 claims description 2
- 229940100198 alkylating agent Drugs 0.000 claims description 2
- 239000012295 chemical reaction liquid Substances 0.000 claims description 2
- 239000012043 crude product Substances 0.000 claims description 2
- 238000010438 heat treatment Methods 0.000 claims description 2
- DQEUYIQDSMINEY-UHFFFAOYSA-M magnesium;prop-1-ene;bromide Chemical compound [Mg+2].[Br-].[CH2-]C=C DQEUYIQDSMINEY-UHFFFAOYSA-M 0.000 claims description 2
- GRFZLHMBAJDCQF-UHFFFAOYSA-M magnesium;prop-1-ene;iodide Chemical compound [Mg+2].[I-].[CH2-]C=C GRFZLHMBAJDCQF-UHFFFAOYSA-M 0.000 claims description 2
- 230000007935 neutral effect Effects 0.000 claims description 2
- 229920000137 polyphosphoric acid Polymers 0.000 claims description 2
- 230000001105 regulatory effect Effects 0.000 claims 1
- 239000002994 raw material Substances 0.000 abstract description 6
- 238000003547 Friedel-Crafts alkylation reaction Methods 0.000 abstract description 3
- 238000006981 Stevens rearrangement reaction Methods 0.000 abstract description 3
- 150000001336 alkenes Chemical class 0.000 abstract description 3
- 238000005804 alkylation reaction Methods 0.000 abstract description 3
- 238000000354 decomposition reaction Methods 0.000 abstract description 3
- 238000010534 nucleophilic substitution reaction Methods 0.000 abstract description 3
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 abstract description 3
- 238000006722 reduction reaction Methods 0.000 abstract description 3
- 239000007858 starting material Substances 0.000 abstract description 3
- 230000029936 alkylation Effects 0.000 abstract description 2
- 238000002474 experimental method Methods 0.000 abstract description 2
- 238000002360 preparation method Methods 0.000 abstract description 2
- 230000008569 process Effects 0.000 abstract description 2
- 230000009467 reduction Effects 0.000 abstract description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 17
- RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 10
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 6
- 238000001228 spectrum Methods 0.000 description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 5
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 5
- 229910052739 hydrogen Inorganic materials 0.000 description 5
- 239000001257 hydrogen Substances 0.000 description 5
- 150000001408 amides Chemical class 0.000 description 4
- XYOVOXDWRFGKEX-UHFFFAOYSA-N azepine Chemical compound N1C=CC=CC=C1 XYOVOXDWRFGKEX-UHFFFAOYSA-N 0.000 description 4
- 229940125782 compound 2 Drugs 0.000 description 4
- 229940126214 compound 3 Drugs 0.000 description 4
- 229940125898 compound 5 Drugs 0.000 description 4
- BKIMMITUMNQMOS-UHFFFAOYSA-N nonane Chemical group CCCCCCCCC BKIMMITUMNQMOS-UHFFFAOYSA-N 0.000 description 4
- HYFHYPWGAURHIV-JFIAXGOJSA-N omacetaxine mepesuccinate Chemical compound C1=C2CCN3CCC[C@]43C=C(OC)[C@@H](OC(=O)[C@@](O)(CCCC(C)(C)O)CC(=O)OC)[C@H]4C2=CC2=C1OCO2 HYFHYPWGAURHIV-JFIAXGOJSA-N 0.000 description 3
- 239000012074 organic phase Substances 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229930013930 alkaloid Natural products 0.000 description 2
- 229940125904 compound 1 Drugs 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- HYFHYPWGAURHIV-UHFFFAOYSA-N homoharringtonine Natural products C1=C2CCN3CCCC43C=C(OC)C(OC(=O)C(O)(CCCC(C)(C)O)CC(=O)OC)C4C2=CC2=C1OCO2 HYFHYPWGAURHIV-UHFFFAOYSA-N 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 229960002230 omacetaxine mepesuccinate Drugs 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 230000000171 quenching effect Effects 0.000 description 2
- LFKDJXLFVYVEFG-UHFFFAOYSA-N tert-butyl carbamate Chemical compound CC(C)(C)OC(N)=O LFKDJXLFVYVEFG-UHFFFAOYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 241000488899 Cephalotaxus Species 0.000 description 1
- 241000931913 Cephalotaxus fortunei Species 0.000 description 1
- ONIBWKKTOPOVIA-SCSAIBSYSA-N D-Proline Chemical compound OC(=O)[C@H]1CCCN1 ONIBWKKTOPOVIA-SCSAIBSYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 244000184734 Pyrus japonica Species 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- BHELZAPQIKSEDF-UHFFFAOYSA-N allyl bromide Chemical compound BrCC=C BHELZAPQIKSEDF-UHFFFAOYSA-N 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 238000011929 asymmetric total synthesis Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 150000004694 iodide salts Chemical class 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- BLWYXBNNBYXPPL-RXMQYKEDSA-N methyl (2r)-pyrrolidine-2-carboxylate Chemical compound COC(=O)[C@H]1CCCN1 BLWYXBNNBYXPPL-RXMQYKEDSA-N 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 238000006257 total synthesis reaction Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
本发明公开了一种合成三尖杉碱中间体的方法。本发明是以廉价易得的Boc酰胺化合物为起始原料,经氮烷基化、Stevens重排、亲核取代、烯烃复分解、还原、付克烷基化6步反应合成了用于制备三尖杉碱的中间体。作为该中间体的一条全新合成路线,本发明反应条件温和、操作简单、原材料廉价易得,而且具有较高的反应收率,经实验验证表明,该方法制备中间体的总收率可达到40%,具有制备工艺简单,原料经济性好,后处理工艺容易等特点。
Description
技术领域
本发明涉及到一种药物中间体的合成方法,具体涉及一种合成三尖杉碱中间体的方法。
背景技术
三尖杉碱(Cephalotaxine,I)是首次从日本粗榧和三尖杉的枝叶中分离得到一种结晶性生物碱。三尖杉碱是已发现的多种抗肿瘤活性三尖杉酯碱的母核结构。在各种三尖杉酯碱中,高三尖杉酯碱(Homoharringtonine, II)因具有较好的抗癌活性而受到重视。1978年,我国正式将其纳入临床,主要用于治疗癌症及白血病等疾病。2012年, 美国食品药品监督管理局(FDA)批准高三尖杉酯碱用于治疗慢性粒白血病(CML)适应症。三尖杉碱及高三尖杉酯碱的结构如下:
可以看到,在三尖杉碱分子的结构中,含有一个手性1-氮杂螺[4.4]壬烷的结构单元同时,1-氮杂螺[4.4]壬烷在很多的天然活性生物碱的结构中也都有存在。1972年,Dolby小组完成了三尖杉碱的首次全合成,迄今为止已有几十条合成路线被报道。到目前为止,关于三尖杉碱的合成已经有多条合成路线被报道。1995年,Mori等以 D-(+)-脯氨酸为手性起始原料经19步反应以1.8%的总收率, 完成了天然三尖杉碱的首次不对称全合成(Isono,N.; Mori, M. J. Org. Chem.1995, 60, 115.)。Mori小组合成Mori中间体及三尖杉碱的合成式如下:
Mori小组的合成工作为后续的合成奠定了基础,许多小组通过全新方法合成得到Mori中间体,然后参考Mori的方法再经5步转化进而完成三尖杉碱的合成。例如,2008年,Hayes 等以N-Boc保护的D-(+)-脯氨酸甲酯作为起始原料经16步反应得到Mori中间体(11,12-二甲氧基-3,5,6,8,9,13b-六氢-4H-苯并[d]环戊烷[b]吡咯[1,2-a]氮杂䓬)(Esmieu, W. R.; Worden, S. M.; Catterick, D.; Wilson, C.; Hayes, C. J. Org. Lett. 2008, 10, 3045.)。2012年,Renaud等以(S)-2-羟基环戊烯作为起始原料经18步反应得到了Mori中间体 (Gonçalves-Martin, M. G.; Zigmantas, S.; Renaud, P. Helv. Chim. Acta2012, 95, 2502.)。
但上述合成路线太长,收率较低消耗高,与实际应用相距较远。基于目前报道的合成方法存在的问题,本发明期望提供一种新的Mori中间体合成路线,进而完成三尖杉碱的合成。
发明内容
本发明的目的是提供一种合成三尖杉碱中间体的方法,合成步骤短,操作简单,原料易得,通过合成得到的三尖杉碱中间体,再经5步文献转化,即可完成三尖杉碱的合成,为三尖杉碱的合成的工业化生产提供了一种可能的合成路线。
本发明合成三尖杉碱中间体的方法,包括以下步骤:
(1)N-烷基化Weinreb酰胺化合物的合成:将Boc酰胺化合物1加入有机溶剂中,0℃下加入酸并搅拌反应0.5~1 h脱去Boc保护基;减压蒸除溶剂,将粗产物溶于乙腈,然后向反应液中加入碱和芳基烷基化试剂,加热至75~85℃回流反应(氮烷基化反应)8~12h,反应后经萃取、干燥、柱色谱分离纯化得到N-烷基化Weinreb酰胺化合物2。
所述Boc酰胺化合物的结构式为:。
所述芳基烷基化试剂的结构式为:,其中X为 Cl, Br,I或/>。
所述Boc酰胺化合物与芳基烷基化试剂的摩尔比为1:1~1:3。
所述酸为盐酸,三氟乙酸或硫酸;所述Boc酰胺化合物与酸的摩尔比为1:1~1:5。
所述碱为碳酸钠、碳酸钾、氢氧化钠、氢氧化钾、叔丁醇钾、叔丁醇钠或甲醇钠;所述Boc酰胺化合物与碱的摩尔比为1:2~1:3。
所述有机溶剂为乙腈、二氯甲烷、氯仿、四氢呋喃或甲苯。
(2)烯丙基酰胺化合物的合成:将N-烷基化Weinreb酰胺化合物2溶于有机溶剂,加入碱,最后加入烯丙基卤代物,氮气保护下,75~85℃回流反应10~12 h(Stevens重排反应),反应后冷却,减压蒸除溶剂,经柱色谱分离得到烯丙基酰胺化合物3。
所述烯丙基卤代物的结构式为:,其中Y = Cl, Br或 I
所述N-烷基化Weinreb酰胺化合物与烯丙基卤代物的摩尔比为1:1~1:3。
所述碱为碳酸钠、碳酸钾、氢氧化钠、氢氧化钾、叔丁醇钾、叔丁醇钠或甲醇钠;所述N-烷基化Weinreb酰胺化合物与碱的摩尔比为1:2~1:3。
所述有机溶剂为乙腈、二氯甲烷、氯仿、四氢呋喃或甲苯。
(3)不饱和酮化合物的合成:在氮气保护下将烯丙基酰胺化合物3溶于有机溶剂中,-80~-75℃下加入烯丙基格氏试剂并在此温度下反应(亲核取代反应)0.5~1h,反应完成后,洗涤,减压蒸除溶剂,柱色谱分离得到不饱和酮化合物4。
所述烯丙基格氏试剂为烯丙基氯化镁,烯丙基溴化镁或烯丙基碘化镁;所述烯丙基酰胺化合物与烯丙基格氏试剂的摩尔比为1:2~1:3。
所述有机溶剂为二氯甲烷、四氢呋喃或甲苯。
(4)氮杂螺环化合物的合成:将不饱和酮化合物4溶于有机溶剂中,加入Grubbs(Ⅱ)催化剂,在氮气保护下,于35~45℃下回流反应1~1.5h(烯烃复分解反应), 减压蒸除溶剂,柱色谱分离得到氮杂螺环化合物5。
所述不饱和酮化合物与Grubbs(Ⅱ)催化剂的摩尔比1:0.05~1:0.1。所述有机溶剂为乙腈、二氯甲烷、氯仿、苯或甲苯。
(5)烯丙醇化合物的合成:将还原剂加入到有机溶剂中,然后加入氮杂螺环化合物5,在氮气保护下,于 120 ~140℃下回流反应(还原反应)1~1.5 h,冷却至室温,用稀盐酸调pH至中性,萃取,干燥,减压蒸除溶剂,柱色谱分离得到烯丙醇化合物6。
所述还原剂为异丙醇铝;所述氮杂螺环化合物与还原剂的摩尔比为1:28~1:30;所述有机溶剂为乙醇,二氯甲烷,异丙醇或甲醇。
(6)三尖杉碱中间体的合成:将烯丙醇化合物6 溶于酸试剂中,氮气保护下,于65~75℃搅拌反应(傅克烷基化反应)45~50 h,反应完成后,碱化,萃取,减压蒸除溶剂,柱色谱分离得到三尖杉碱中间体7(11,12-二甲氧基-3,5,6,8,9,13b-六氢-4H-苯并[d]环戊烷[b]吡咯[1,2-a]氮杂䓬)。所述酸试剂为五氧化二磷的甲磺酸溶液或多聚磷酸。
反应式如下:
相比于现有技术的有益效果:本发明以廉价易得的Boc酰胺化合物为起始原料,经氮烷基化、Stevens重排、亲核取代、烯烃复分解、还原、付克烷基化6步反应合成了用于制备三尖杉碱的中间体。作为该中间体的一条全新合成路线,本发明合成路线短、反应条件温和、操作简单、原材料廉价易得,而且具有较高的反应收率,是目前制备Mori中间体最短的合成路线。经实验验证表明,该方法制备Mori中间体的总收率可达到40%,具有制备工艺简单,原料经济性好,后处理工艺容易等特点。
附图说明
图1为N-烷基化Weinreb酰胺化合物的核磁氢谱图;
图2为N-烷基化Weinreb酰胺化合物的核磁碳谱图;
图3为烯丙基酰胺化合物的核磁氢谱图;
图4为烯丙基酰胺化合物的核磁碳谱图;
图5为不饱和酮化合物的核磁氢谱图;
图6为不饱和酮化合物的核磁碳谱图;
图7为氮杂螺环化合物的核磁氢谱图;
图8为氮杂螺环化合物的核磁碳谱图;
图9为烯丙醇化合物的核磁氢谱图;
图10为烯丙醇化合物的核磁碳谱图;
图11为11,12-二甲氧基-3,5,6,8,9,13b-六氢-4H-苯并[d]环戊烷[b]吡咯[1,2-a]氮杂䓬(三尖杉碱中间体)的的核磁氢谱图(与此前文献报道的该化合物的核磁氢谱数据完全吻合)。
具体实施方式
下面通过具体实施例对本发明合成三尖杉碱中间体的方法作进一步说明。
实施例
(1)N-烷基化Weinreb酰胺化合物的合成
将Boc酰胺化合物1(472 mg,1.83 mmol)加入盛有10mL二氯甲烷瓶中,0℃下加入三氟乙酸0.5 mL,搅拌0.5 h后,反应液浓缩,然后加入K2CO3 (631 mg,4.58 mmol)以及碘代物()(1.07 g,3.66 mmol),再加入5mL乙腈溶液,加热至80℃回流10h。反应完全后,加适量水淬灭,倒入分液漏斗,乙酸乙酯萃取多次,合并有机相,饱和食盐水洗一次,无水硫酸钠干燥。减压蒸除溶剂,经柱色谱分离得到黄色油状N-烷基化Weinreb酰胺化合物2,收率80%,IR (film): vmax 2938, 2834, 1668, 1590, 1516, 1463, 1261, 1156, 1029 cm-1.1H NMR (400 MHz, CDCl3) δ: 1.77-1.85 (m, 2H), 1.91-1.97 (m, 1H), 2.08-2.13 (m,1H), 2.36 (q, 1H, J = 8.4 Hz), 2.47-2.54 (m, 1H), 2.74 (t, 2H, J = 8.0 Hz),2.83-2.90 (m, 1H), 3.15 (s, 3H), 3.30 (td, 1H, J = 8.4, 2.8 Hz), 3.48 (t, 1H,J = 7.6 Hz), 3.63 (s, 3H), 3.80 (s, 3H), 3.82 (s, 3H), 6.69-6.75 (m, 3H) ppm.13C NMR (100 MHz, CDCl3) δ: 23.10, 29.09, 32.47, 35.00, 53.32, 55.76, 55.83,56.83, 61.26, 63.55, 111.19, 112.06, 120.42, 133.07, 147.20, 148.71, 175.00ppm. HRMS (ESI) m/z calcd. for C17H27N2O4 (M+H)+ : 323.1971, found: 323.1973.
(2)烯丙基酰胺化合物的合成
取50 mL双口瓶,先加入K2CO3 (805 mg,5.83 mmol),置换氮气。将N-烷基化Weinreb酰胺化合物2 (853 mg,2.65 mmol)溶于乙腈加入瓶中,最后加入烯丙基溴(0.47mL,5.3 mmol),80℃回流11 h后冷却。减压蒸除溶剂,经柱色谱分离得到浅黄色油状烯丙基酰胺化合物3,收率97%,IR (film): vmax 2936, 2833, 1647, 1590, 1515, 1463, 1262,1156, 1029 cm-1. 1H NMR (400 MHz, CDCl3) δ: 1.75-1.81 (m, 2H), 1.88-1.95 (m,1H), 2.13 (m, 1H), 2.27 (dd, 1H, J = 13.6, 7.6 Hz), 2.66-2.80 (m, 5H), 3.02-3.11 (m, 2H), 3.13 (s, 3H), 3.59 (s, 3H), 3.83 (s, 3H), 3.85 (s, 3H), 5.00-5.05 (m, 2H), 5.77-5.88 (m, 1H), 6.69-6.71 (m, 2H), 6.75 (d, 1H, J = 8.4 Hz)ppm. 13C NMR (100 MHz, CDCl3) δ: 22.66, 32.92, 34.16, 35.61, 37.48, 50.96,51.04, 55.77, 55.89, 60.09, 70.71, 111.14, 111.97, 117.08, 120.54, 133.41,135.93, 147.20, 148.72, 175.60 ppm. HRMS (ESI) m/z calcd. for C20H31N2O4 (M+H)+: 363.2284, found: 363.2267.
(3)不饱和酮化合物的合成
在氮气保护下将烯丙基酰胺化合物3 (288 mg,0.80 mmol)溶于四氢呋喃加入瓶中,-78℃下加入烯丙基氯化镁(2.40 mL,2.40 mmol),反应0.5 h。反应完全后,加NH4Cl溶液淬灭,倒入分液漏斗,加乙酸乙酯10 mL,有机相水洗一次,食盐水洗涤,减压蒸除溶剂,柱色谱分离得到浅黄色油状不饱和酮化合物4,收率86%,IR (film): vmax 3071, 2938,2831, 1687, 1515, 1463, 1262, 1156, 1030 cm-1. 1H NMR (400 MHz, CDCl3) δ: 1.77(d, 2H, J = 7.2, 2.0 Hz), 1.84-1.91 (m, 4H), 2.04 (d, 1H, J = 5.2 Hz), 2.16(q, 1H, J = 8.0 Hz), 2.52-2.57 (m, 1H), 2.61-2.78 (m, 5H), 3.21-3.25 (m, 1H),3.83 (s, 3H), 3.84 (s, 3H), 5.01 (t, 2H, J = 14.0 Hz), 5.77-5.87 (m, 1H),6.39 (dd, 1H, J = 15.2, 1.6 Hz), 6.66 (t, 2H, J = 8.0 Hz), 6.75 (d, 1H, J =8.0 Hz), 6.78-6.88 (dt, 1H, J = 22.0, 6.8 Hz) ppm. 13C NMR (100 MHz, CDCl3) δ:18.14, 23.19, 32.95, 35.47, 35.53, 50.77, 51.21, 55.76, 55.82, 72.66, 111.04,112.01, 117.10, 120.61, 126.78, 133.10, 135.88, 141.75, 147.23, 148.67,202.14 ppm. HRMS (ESI) m/z calcd. for C21H30NO3 (M+H)+ : 344.2226, found:344.2217.
(4)氮杂螺环化合物的合成
取25 mL双口瓶,先加入Grubbs(Ⅱ)催化剂(19mg,0.0225 mmol),进行氮保护气。然后将不饱和酮化合物4 (154 mg,0.45 mmol)溶于二氯甲烷加入瓶中,40℃回流1h后,减压蒸除溶剂,柱色谱分离得到棕色油状氮杂螺环化合物5,收率90%,IR (film): vmax 2936,2832, 1700, 1587, 1515, 1463, 1261, 1156, 1028 cm-1. 1H NMR (400 MHz, CDCl3)δ: 1.83 (d, 1H, J = 8.0 Hz), 1.89-1.96 (m, 1H), 2.01-2.14 (m, 2H), 2.53-2.79(m, 6H), 3.04 (s, 1H), 3.16-3.20 (m, 1H), 3.83 (s, 3H), 3.85 (s, 3H), 6.10(d, 1H, J = 4.0 Hz), 6.68-6.77 (m, 3H), 7.60-7.63 (m, 1H) ppm.13C NMR (100MHz, CDCl3) δ: 21.82, 35.67, 36.82, 39.22, 51.47, 51.83, 55.77, 55.82, 70.94,111.11, 112.01, 120.42, 132.93, 133.36, 147.25, 148.66, 162.35, 212.61 ppm.HRMS (ESI) m/z calcd. for C18H24NO3 (M+H)+ : 302.1756, found: 302.1760.
(5)烯丙醇化合物的合成
取25 mL双口瓶,加入异丙醇铝(773 mg,3.78 mmol),置换氮气,加入异丙醇溶液5mL共沸,然后将氮杂螺环化合物5 (38 mg,0.13 mmol)溶于异丙醇加入瓶中,130 ℃回流1h后,将溶剂蒸除,残渣搅拌3 h。冷却至室温,用稀盐酸调pH至中性,二氯甲烷萃取多次,合并有机相,干燥。减压蒸除溶剂,柱色谱分离得到烯丙醇化合物6,收率89%,IR (film): vmax3438, 2964, 1647, 1517, 1261, 1159, 1023 cm-1.1H NMR (400 MHz, CDCl3) δ: 1.25(s, 1H), 1.77-1.89 (m, 3H), 2.05-2.15 (m, 2H), 2.50-2.60 (m, 2H), 2.69-2.82(m, 3H), 2.99 (d, 1H, J = 9.2 Hz), 3.37 (m, 1H), 3.84 (s, 3H), 3.86 (s, 3H),4.23 (s, 1H), 5.79 (t, 2H, J = 8.4 Hz), 6.69-6.73 (m, 2H), 6.79 (d, 1H, J =8.0 Hz) ppm. 13C NMR (100 MHz, CDCl3) δ: 22.88, 35.30, 38.07, 38.96, 52.83,55.83, 72.61, 80.45, 111.8, 112.04, 120.56, 130.93, 132.06, 134.33, 147.45,148.81 ppm. HRMS (ESI) m/z calcd. for C18H26NO3 (M+H)+ : 304.1913, found:304.1899.
(6)11,12-二甲氧基-3,5,6,8,9,13b-六氢-4H-苯并[d]环戊烷[b]吡咯[1,2-a]氮杂䓬(三尖杉碱中间体7)的合成
取10 mL单口瓶,将烯丙醇化合物6 (35 mg,0.115 mg)加入至6 mL 7.7 wt% 的五氧化二磷的甲磺酸溶液中,置换氮气。混合物在70℃搅拌48 h。冷却,恢复室温,再加入10mL饱和NaHCO3溶液,再加入NaOH固体调pH至10,然后用二氯甲烷萃取多次,无水Na2SO4干燥,减压蒸除溶剂,柱色谱分离(DCM : MeOH = 10 : 1),得到11,12-二甲氧基-3,5,6,8,9,13b-六氢-4H-苯并[d]环戊烷[b]吡咯[1,2-a]氮杂䓬(25 mg,75%)。1H NMR (400 MHz,CDCl3) δ: 0.86-0.89 (m, 1H), 1.25 (s, 3H), 1.78-1.83 (m, 2H), 2.06-2.10 (m,3H), 2.40 (q, 1H, J = 8.0 Hz), 2.53 (s, 1H), 2.73 (s, 1H), 2.85 (d, 1H, J =20.0 Hz), 3.01-3.06 (m, 1H), 3.19-3.27 (m, 1H), 3.84 (s, 3H), 3.86 (s, 3H),5.53-5.57 (m, 1H), 5.78-5.82 (m, 1H), 6.62 (s, 1H), 6.69 (s, 1H). 13C NMR (100MHz, CDCl3) δ: 147.66, 147.12, 132.53, 131.18, 130.89, 128.72, 144.11,113.15, 68.23, 62.33, 56.22, 56.76, 53.80, 49.11, 43.46, 34.77, 30.63, 20.11;HRMS(ESI)caled for C18H23NO2 (M+H)+ 286.1728, found 286.1723.
Claims (10)
1.一种合成三尖杉碱中间体的方法,包括以下步骤:
(1)N-烷基化Weinreb酰胺化合物的合成:将Boc酰胺化合物加入有机溶剂中,0℃下加入酸并在此温度下搅拌反应0.5~1 h;减压蒸除溶剂,然后将粗产物溶于乙腈中,再向反应液中加入碱和芳基烷基化试剂,加热至75~85℃回流反应8~12h,反应后经萃取、干燥、柱色谱分离纯化得到N-烷基化Weinreb酰胺化合物;
所述Boc酰胺化合物的结构式为:;
所述芳基烷基化试剂的结构式为:,其中X为 Cl, Br, I或/>;
N-烷基化Weinreb酰胺化合物的结构式为:;
(2)烯丙基酰胺化合物的合成:将N-烷基化Weinreb酰胺化合物溶于有机溶剂,加入碱,最后加入烯丙基卤代物,氮气保护下,75~85℃回流反应10~12 h ,反应后冷却,减压蒸除溶剂,经柱色谱分离得到烯丙基酰胺化合物;
所述烯丙基卤代物的结构式为:,其中Y = Cl, Br或 I;
所述烯丙基酰胺化合物的结构式为:;
(3)不饱和酮化合物的合成:在氮气保护下将烯丙基酰胺化合物溶于有机溶剂中,-80~-75℃下加入烯丙基格氏试剂并在此温度下反应0.5~1h,反应完成后,洗涤,减压蒸除溶剂,柱色谱分离得到不饱和酮化合物;
所述不饱和酮化合物的结构式为:
(4)氮杂螺环化合物的合成:将不饱和酮化合物溶于有机溶剂中,加入Grubbs(Ⅱ)催化剂,在氮气保护下,于35~45℃下回流反应1~1.5h,减压蒸除溶剂,柱色谱分离得到氮杂螺环化合物;
所述氮杂螺环化合物的结构式为:;
(5)烯丙醇化合物的合成:将还原剂加入到有机溶剂中,然后加入氮杂螺环化合物,在氮气保护下,于120 ~140℃下回流反应1~1.5 h,冷却至室温,用稀盐酸调pH至中性,萃取,干燥,减压蒸除溶剂,柱色谱分离得到烯丙醇化合物;
所述烯丙醇化合物的结构式为:;
(6)三尖杉碱中间体的合成:将烯丙醇化合物溶于酸试剂中,氮气保护下,于65~75℃搅拌反应45~50 h,反应完成后,碱化,萃取,减压蒸除溶剂,柱色谱分离得到三尖杉碱中间体;
所述三尖杉碱中间体的结构式为:。
2.根据权利要求1所述一种合成三尖杉碱中间体的方法,其特征在于:步骤(1)中,所述Boc酰胺化合物与芳基烷基化试剂的摩尔比为1:1~1:3。
3.根据权利要求1所述一种合成三尖杉碱中间体的方法,其特征在于:步骤(1)中,所述酸为盐酸,三氟乙酸或硫酸,所述Boc酰胺化合物与酸的摩尔比为1:1~1:5;所述碱为碳酸钠、碳酸钾、氢氧化钠、氢氧化钾、叔丁醇钾、叔丁醇钠或甲醇钠,所述Boc酰胺化合物与碱的摩尔比为1:2~1:3。
4.根据权利要求1所述一种合成三尖杉碱中间体的方法,其特征在于:步骤(1)、(2)中,所述有机溶剂为乙腈、二氯甲烷、氯仿、四氢呋喃或甲苯。
5.根据权利要求1所述一种合成三尖杉碱中间体的方法,其特征在于:步骤(2)中,所述N-烷基化Weinreb酰胺化合物与烯丙基卤代物的摩尔比为1:1~1:3。
6.根据权利要求1所述一种合成三尖杉碱中间体的方法,其特征在于:步骤(2)中,所述碱为碳酸钠、碳酸钾、氢氧化钠、氢氧化钾、叔丁醇钾、叔丁醇钠或甲醇钠,所述N-烷基化Weinreb酰胺化合物与碱的摩尔比为1:2~1:3。
7.根据权利要求1所述一种合成三尖杉碱中间体的方法,其特征在于:步骤(3)中,所述烯丙基格氏试剂为烯丙基氯化镁,烯丙基溴化镁或烯丙基碘化镁,所述烯丙基酰胺化合物与烯丙基格氏试剂的摩尔比为1:2~1:3;所述有机溶剂为二氯甲烷、四氢呋喃或甲苯。
8.根据权利要求1所述一种合成三尖杉碱中间体的方法,其特征在于:步骤(4)中,所述不饱和酮化合物与Grubbs(Ⅱ)催化剂的摩尔比1:0.05~1:0.1;所述有机溶剂为乙腈、二氯甲烷、氯仿、苯或甲苯。
9.根据权利要求1所述一种合成三尖杉碱中间体的方法,其特征在于:步骤(5)中,所述还原剂为异丙醇铝;所述氮杂螺环化合物与还原剂的摩尔比为1:28~1:30;所述有机溶剂为乙醇,二氯甲烷,异丙醇或甲醇。
10.根据权利要求1所述一种合成三尖杉碱中间体的方法,其特征在于:步骤(6)中,所述酸试剂为五氧化二磷的甲磺酸溶液或多聚磷酸。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111499183.2A CN113999241B (zh) | 2021-12-09 | 2021-12-09 | 一种合成三尖杉碱中间体的方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111499183.2A CN113999241B (zh) | 2021-12-09 | 2021-12-09 | 一种合成三尖杉碱中间体的方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113999241A CN113999241A (zh) | 2022-02-01 |
CN113999241B true CN113999241B (zh) | 2024-03-26 |
Family
ID=79931568
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111499183.2A Active CN113999241B (zh) | 2021-12-09 | 2021-12-09 | 一种合成三尖杉碱中间体的方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113999241B (zh) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006055578A2 (en) * | 2004-11-16 | 2006-05-26 | Temple University - Of The Commonwealth Systems Of Higher Education | Asymmetric synthesis of (-)-agelastatin a |
CN101585840A (zh) * | 2009-06-18 | 2009-11-25 | 南开大学 | 光学纯的α-酮酰基三尖杉酯碱及其制备纯化方法 |
CN101691375A (zh) * | 2009-08-05 | 2010-04-07 | 兰州大学 | 合成三尖杉碱的中间体的制备方法 |
WO2017097245A1 (zh) * | 2015-12-10 | 2017-06-15 | 南开大学 | 三尖杉酯类生物碱、其制备方法和用途 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8466142B2 (en) * | 2008-03-03 | 2013-06-18 | Sloan-Kettering Institute For Cancer Research | Cephalotaxus esters, methods of synthesis, and uses thereof |
WO2010103405A2 (en) * | 2009-03-11 | 2010-09-16 | Jean-Pierre Robin | Process for preparing cephalotaxine esters |
-
2021
- 2021-12-09 CN CN202111499183.2A patent/CN113999241B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006055578A2 (en) * | 2004-11-16 | 2006-05-26 | Temple University - Of The Commonwealth Systems Of Higher Education | Asymmetric synthesis of (-)-agelastatin a |
CN101585840A (zh) * | 2009-06-18 | 2009-11-25 | 南开大学 | 光学纯的α-酮酰基三尖杉酯碱及其制备纯化方法 |
CN101691375A (zh) * | 2009-08-05 | 2010-04-07 | 兰州大学 | 合成三尖杉碱的中间体的制备方法 |
WO2017097245A1 (zh) * | 2015-12-10 | 2017-06-15 | 南开大学 | 三尖杉酯类生物碱、其制备方法和用途 |
Non-Patent Citations (4)
Title |
---|
A Palladium-Catalyzed Asymmetric Allylic Alkylation Approach to α‑Quaternary γ‑Butyrolactones;Marllon Nascimento de Oliveira等;《Org. Lett.》;14-17以及supporting information * |
Abdul Hameed等.A Second Generation Formal Synthesis of (-)-Cephalotaxine.《J. Org. Chem.》.2008,8045-8048. * |
Total Synthesis of (-)-Cephalotaxine;Naohiro Isono等;《J. Org. Chem.》;115-119 * |
Tuning of Regioselectivity in Inorganic Iodide-Catalyzed Alkylation of 2-Methoxyfurans via Electronic and Steric Effects;Jie Chen等;《Adv. Synth. Catal.》;第354卷;1114-1128 * |
Also Published As
Publication number | Publication date |
---|---|
CN113999241A (zh) | 2022-02-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2044076B1 (en) | Process for the preparation of asenapine and intermediate products used in said process. | |
Hadden et al. | Synthesis of the heterocyclic core of martinelline and martinellic acid | |
Liu et al. | Oxidative dearomatization/intramolecular Diels–Alder cycloaddition cascade for the syntheses of (±)-atisine and (±)-isoazitine | |
WO2010028232A1 (en) | Process and intermediates for the synthesis of 8-[{1-(3,5-bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one compounds | |
EP2598496B1 (en) | Novel process for the preparation of asenapine | |
Kuehne et al. | Total syntheses of tubotaiwine and 19, 20-dihydro-20-epi-akuammicine | |
Xiong et al. | Ring Expansion of 4-Alkynylcyclobutenones. Synthesis of Enantiomerically Pure Pyranoquinones from 4-(4-Oxo-1, 6-enynyl)-4-hydroxycyclobutenones and 4-(4-Oxo-1, 6-dialkynyl)-4-hydroxycyclobutenones | |
CN113999241B (zh) | 一种合成三尖杉碱中间体的方法 | |
Alcaide et al. | Gold/acid-cocatalyzed regiodivergent preparation of bridged ketals via direct bis-oxycyclization of alkynic acetonides | |
Booker-Milburn et al. | A concise synthesis of 7-desmethylasteriscanolide and the discovery of an unusual fragmentation reaction to the related asteriscunolide skeleton | |
CN108530241B (zh) | 一种具有苄位季碳中心的苯并环衍生物的制备方法 | |
CN110078622B (zh) | 一种4-乙氧基-1,1,2,4,5,6-六氢环丁烷并萘-2-苯甲酸酯的合成方法 | |
CN111646964A (zh) | 一种碱催化的合成2h-吡喃-2-酮衍生物新方法 | |
Korotaev et al. | Highly diastereoselective synthesis of novel 2, 3, 4-trisubstituted chromanes via the reaction of 3-nitro-2-(trihalomethyl)-and 3-nitro-2-phenyl-2H-chromenes with 1-morpholinocyclopentene | |
EP1856124B1 (en) | New synthesis of a camptothecin subunit | |
Stammel et al. | Synthesis and X‐ray Analysis of New [5] Helicenes–HMO Calculations on the Photocyclization of the Stilbene Precursors | |
Cui et al. | Total synthesis of (+)-lentiginosine via a key Au catalysis | |
Voskressensky et al. | On the reaction of fused benzodiazepines with alkynes containing electron-withdrawing groups | |
CN117164586B (zh) | 一种螺环双胺的制备方法 | |
CN115353521B (zh) | 一种复杂3′-螺环吲哚里西定结构的合成方法 | |
CN111018771B (zh) | 一种合成3-(2-氰基乙烯基)吲哚衍生物的方法 | |
CN115477624B (zh) | 一种芳基胺类化合物制备方法 | |
CN107628998B (zh) | 一类lepadin生物碱合成中间体的制备方法 | |
CN112126941B (zh) | 一种多取代10-羟基菲衍生物及其制备方法 | |
Wang et al. | Unusual reactions of a 7, 17-seco-type C19-diterpenoid alkaloid derived from deltaline |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |